MAD Refractory: Solid Tumor QD w/o Break
NCT00207012
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
45
Enrollment
INDUSTRY
Sponsor class
Conditions
HER2 or EGFR Expressing Advanced Solid Malignancies
Interventions
DRUG:
BMS-599626
Sponsor
Bristol-Myers Squibb